GCIG-Consensus guideline for Long-term survivorship in gynecologic Cancer: A position paper from the gynecologic cancer Intergroup (GCIG) symptom benefit committee

Woopen, Hannah; Sehouli, Jalid; Davis, Alison; Lee, Y.C.; Cohen, Paul A.; Ferrero, Annamaria; Gleeson, Noreen; Jhingran, Anuja; Kajimoto, Yusuke; Mayadev, J.; Barretina-Ginesta, Maria Pilar; Sundar, Sudha; Suzuki, Nao; Dorst, E.B.L. van; Joly, Florence

doi:10.1016/j.ctrv.2022.102396

Cited by 8 publications

(4 citation statements)

References 82 publications

(86 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interim analyses of the Expression VI survey have influenced the GCIG consensus guideline on long-term survival with gynecological cancer [5]. This present analysis of 1044 long-term survivors with ovarian cancer has now confirmed the symptom checklist and clinical relevance of the consensus paper.…”

Section: Discussionsupporting

confidence: 60%

“…A growing number of survivors receive long-term treatment including targeted therapies [2][3][4]. This is reflected by the recent definition of long-term survival with ovarian cancer with a survival of at least five years after initial diagnosis, independently from the current status of the disease and history of recurrences [5]. To date, prospective data to evaluate prognostic factors for long-term survival are scarce.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Side Effects from Cancer Therapies and Perspective of 1044 Long-Term Ovarian Cancer Survivors—Results of Expression VI–Carolin Meets HANNA–Holistic Analysis of Long-Term Survival with Ovarian Cancer: The International NOGGO, ENGOT, and GCIG Survey

Woopen,

Keller,

Zocholl

et al. 2023

Cancers

View full text Add to dashboard Cite

The aim of this survey was to increase the knowledge on the characteristics and health concerns of long-term survivors (LTS; survival > 5 years) after ovarian cancer in order to tailor follow-up care. This international survey was initiated by the NOGGO and was made available to members of ENGOT and GCIG. The survey is anonymous and consists of 68 questions regarding sociodemographic, medical (cancer) history, health concerns including distress, long-term side effects, and lifestyle. For this analysis, 1044 LTS from 14 countries were recruited. In total, 58% were diagnosed with FIGO stage III/IV ovarian cancer and 43.4% developed recurrent disease, while 26.0% were receiving cancer treatment at the time of filling in the survey. LTS who survived 5–10 years self-estimated their health status as being significantly worse than LTS who survived more than 10 years (p = 0.034), whereas distress also remained high 10 years after cancer diagnosis. Almost half of the cohort (46.1%) reported still having symptoms, which were mainly lymphedema (37.7%), fatigue (23.9%), pain (21.6%), polyneuropathy (16.9%), gastrointestinal problems (16.6%), and memory problems (15.5%). Almost all patients (94.2%) regularly received follow-up care. Specialized survivorship care with a focus on long-term side effects, lifestyle, and prevention should be offered beyond the typical five years of follow-up care.

show abstract

Section: Discussionsupporting

confidence: 60%

Section: Introductionmentioning

confidence: 99%

Side Effects from Cancer Therapies and Perspective of 1044 Long-Term Ovarian Cancer Survivors—Results of Expression VI–Carolin Meets HANNA–Holistic Analysis of Long-Term Survival with Ovarian Cancer: The International NOGGO, ENGOT, and GCIG Survey

Woopen,

Keller,

Zocholl

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…The ve years is widely acknowledged as the cut-off point to distinguish the high and low rates of potential CC recurrence and metastasis. [13] However, it doesn't mean CC survivors are "safe" after ve years. CC survivors could still acquire SPMs in their lifetime since more than 80% CCSPMs occurred ve years later in our study.…”

Section: Patient Characteristicsmentioning

confidence: 99%

Nomograms Constructed for Predicting Diagnosis and Prognosis in Cervical Cancer Patients with Second Primary Malignancies: A SEER Database Analysis

Xie

Lin

Liu

et al. 2023

Preprint

View full text Add to dashboard Cite

Purpose Cervical cancer (CC) patients are more likely to develop second primary malignancies (SPMs) than general population. With the advancement in cancer therapy, CC patients are achieving long-term survival, leading SPMs to our attention. Our study aims to establish diagnostic and prognostic nomograms for CC patients with second primary malignancies (CCSPMs) to help make personalized follow-up plans and treatments. Methods Data of CCSPMs between 2000 and 2019 was extracted from SEER. The proportions and the average interval time of CCSPM onset were calculated. 11 related clinical characteristics, including age, race, marital status, grade, FIGO stage, radiotherapy, chemotherapy, and surgery, were further explore. Logistic and Cox regressions were employed to predict risk factors for CCSPMs diagnosis. Finally, two nomograms were developed to predict the probability occurrence and prognosis of CCSPMs, respectively. Results For diagnostic nomogram construction, 59,178 CC patients were randomly divided into training (n = 41,426) and validation cohorts (n = 17,752). For prognostic nomogram construction, 3,527 CCSPMs patients were randomly divided into training (n = 2,469) and validation cohorts (n = 1,058). The diagnostic nomogram consisting of above eleven independent risk factors (all P < 0.05), had high accuracy (AUCtraining = 0.851 and AUCvalidating = 0.845). The prognostic nomogram integrated with eight independent prognostic factors such as treatments, FIGO stage and TNM stage, performed well in predicting 5-year OS (AUCtraining = 0.835 and AUCvalidating = 0.837). Conclusion Our diagnostic and prognostic nomograms could facilitate clinicians to quantify individual SPMs risk and survival probabilities and optimize the surveillance recommendations and personalized clinical decision-making.

show abstract

“…Cardiovascular mortality is the leading cause of death in EC survivors [ 9 , 10 ], and they share the same manifestations and risks as women without this cancer [ 11 , 12 , 13 ]. In a Japanese cohort that survived EC, HT produced a superior disease-free survival rate compared to ovarian conservation, according to a recent multicentric retrospective cohort [ 14 ].…”

Section: Introductionmentioning

confidence: 99%

Quantification of Women Who Could Benefit from Hormone Therapy after Endometrial Cancer Treatment: An Analysis of SEER Data

et al. 2022

View full text Add to dashboard Cite

Our primary aim was to estimate the magnitude of stage I endometrial cancer (EC) survivors that could benefit from hormonal therapy (HT). Our secondary aims were to assess EC incidence in women below 50 and below 60 over the years, and analyze the overall survival and any influencing factors. We analyzed the endometrioid EC data from the Surveillance, Epidemiology, and End Results (SEER) program according to women’s age, tumor stage, and grade. We analyzed the proportions of EC survivors below 50 and below 60 years of age and stratified those age groups by race. For age distribution and survival analysis SEER, 18 registries’ research data (2000–2018) were analyzed. We analyzed the SEER 12 registries’ research data (1992–2019) for incidence time trends. Our investigation found a 14% and 40% cumulative prevalence of stage I EC that occurs in women below 50 or 60 years, respectively. EC’s prevalence has progressively risen in recent decades, but cancer-specific mortality remains low. The increasing number of women affected by EC in premenopause or early postmenopause face an 18 years-survival rate of 96.86% and 95.73%, respectively. A significant proportion of low-grade EC survivors can potentially benefit from HT treatment, and this requires awareness of other aspects of their health or quality of life, in addition to cancer treatments.

show abstract

GCIG-Consensus guideline for Long-term survivorship in gynecologic Cancer: A position paper from the gynecologic cancer Intergroup (GCIG) symptom benefit committee

Cited by 8 publications

References 82 publications

Side Effects from Cancer Therapies and Perspective of 1044 Long-Term Ovarian Cancer Survivors—Results of Expression VI–Carolin Meets HANNA–Holistic Analysis of Long-Term Survival with Ovarian Cancer: The International NOGGO, ENGOT, and GCIG Survey

Side Effects from Cancer Therapies and Perspective of 1044 Long-Term Ovarian Cancer Survivors—Results of Expression VI–Carolin Meets HANNA–Holistic Analysis of Long-Term Survival with Ovarian Cancer: The International NOGGO, ENGOT, and GCIG Survey

Nomograms Constructed for Predicting Diagnosis and Prognosis in Cervical Cancer Patients with Second Primary Malignancies: A SEER Database Analysis

Quantification of Women Who Could Benefit from Hormone Therapy after Endometrial Cancer Treatment: An Analysis of SEER Data

Contact Info

Product

Resources

About